-
公开(公告)号：US10696722B2
公开(公告)日：2020-06-30
申请号：US16323839
申请日：2017-08-10
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting.
-
2.发明申请公开(公告)号：US20190169252A1
公开(公告)日：2019-06-06
申请号：US16323839
申请日：2017-08-10
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting.
-
Patent Agency Ranking
公开(公告)号：US11078249B2
公开(公告)日：2021-08-03
申请号：US16886177
申请日：2020-05-28
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting.
-
公开(公告)号：US11692019B2
公开(公告)日：2023-07-04
申请号：US16886184
申请日：2020-05-28
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
CPC classification number: C07K14/5434 , A61K38/208 , C07K14/54 , C07K14/59 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein. The heterodimeric Fc-fused protein according to the present invention has an advantage in that it can retain the activity of a naturally occurring physiologically active protein whose two or more different subunits exhibit physiological activity by forming a protein complex, because the physiologically active protein can be linked to an immunoglobulin heterodimeric Fc such that the naturally occurring form and structure of the fused protein thereof can be maintained. When the heterodimeric Fc-fused protein according to the present invention is used, there is an advantage in that the in vivo half-life of the physiologically active protein contained in the heterodimeric Fc-fused protein can be significantly increased due to the Fc-mediated long half-life such that various physiological activities thereof in vivo can be long-lasting.
-
公开(公告)号：US12216129B2
公开(公告)日：2025-02-04
申请号：US17292050
申请日：2019-11-07
Inventor： Yong Sung Kim , Hae-Sim Park , Jung Eun Kim , Keunok Jung
Abstract: An antibody or antigen-binding fragment thereof, which binds with a high pM-level affinity to a human IL-4 receptor alpha chain that is a human IL-4 receptor, is provided. The antibody or antigen-binding fragment has a different epitope and a different antigen dissociation rate than existing antibodies. A nucleic acid encoding the antibody or antigen-binding fragment thereof, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a conjugate comprising the antibody or antigen-binding fragment thereof, a composition for preventing or treating inflammatory diseases, and a composition for diagnosing inflammatory diseases are disclosed.
-
公开(公告)号：US20230416325A1
公开(公告)日：2023-12-28
申请号：US18323124
申请日：2023-05-24
Inventor： Yong Sung Kim , Keunok Jung , Ji Hee Ha , Dong Ki Choi , Hye Ji Choi , Ye Jin Kim
CPC classification number: C07K14/5434 , A61K38/208 , C07K14/59 , C07K14/54 , A61K38/00
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
-
7.发明申请公开(公告)号：US20200276328A1
公开(公告)日：2020-09-03
申请号：US16645007
申请日：2018-09-07
Inventor： Yong Sung Kim , Ye Jin Kim , Keunok Jung , Jeong-Ah Kim
IPC: A61K47/68 , A61K38/10 , A61K39/395 , A61P35/00 , A61K45/06
Abstract: The present invention relates to a composition for inhibiting regulatory T cell immunosuppression, containing a fusion protein comprising a peptide that binds specifically to neuropilin 1 (NRP1). The fusion protein comprising the peptide that binds specifically to neuropilin 1 according to the present invention can reduce the proportion of regulatory T cells among CD4+ T cells in tumor tissue and inhibit the activity of regulatory T cells that infiltrated into tumor tissue, thereby down-regulating immunosuppression in the tumor tissue without causing systemic toxicity. Thus, the fusion protein can exhibit a high effect on tumor treatment.
-
-
-
-
-
-
Search Results
7
records
(took 0.016 seconds)
